Avoro Capital Advisors LLC
Institutional investor · Portfolio as of Q4 2023
Top Holdings42 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
APELLIS PHARMACEUTICALS INC | 11.1M | $665.1M | 9.2% | $43.88 | +36.41% | 12 qtrssince 2021-Q1 | Unchanged 0 |
UNITED THERAPEUTICS CORP | 2.9M | $628.6M | 8.7% | $151.50 | +45.14% | 13 qtrssince 2020-Q4 | Increased 62 |
ASCENDIS PHARMA A/S | 3.8M | $473M | 6.5% | $121.46 | +3.70% | 11 qtrssince 2021-Q2 | Increased 63 |
ARGENX SE - ADR | 1.2M | $469.7M | 6.5% | $224.48 | +69.47% | 20 qtrssince 2019-Q1 | Increased 75 |
MADRIGAL PHARMACEUTICALS INC | 1.9M | $437.1M | 6.0% | $146.73 | +57.69% | 20 qtrssince 2019-Q1 | Increased 74 |
AVI BIOPHARMA INC | 4.3M | $418.9M | 5.8% | $107.06 | -9.93% | 20 qtrssince 2019-Q1 | Increased 67 |
BIOMARIN PHARMACEUTICAL INC | 4.3M | $414.6M | 5.7% | $87.07 | +10.73% | 20 qtrssince 2019-Q1 | Increased 69 |
SPDR S&P BIOTECH ETF | 4.4M | $396.8M | 5.5% | $88.83 | 0.00% | 1 qtr | New 97 |
AMICUS THERAPEUTICS INC | 27.4M | $388.8M | 5.4% | $11.07 | +28.20% | 20 qtrssince 2019-Q1 | Unchanged 0 |
CEREVEL THERAPEUTICS HLDNG I | 7.6M | $320.4M | 4.4% | — | — | 2 qtrssince 2023-Q3 | Increased 93 |
Krystal Biotech, Inc. | 2.6M | $318.3M | 4.4% | $85.59 | +44.94% | 9 qtrssince 2021-Q4 | Unchanged 0 |
MIRATI THERAPEUTICS INC | 4.9M | $287.1M | 4.0% | — | — | 20 qtrssince 2019-Q1 | Decreased 0 |
CYMABAY THERAPEUTICS INC | 11.1M | $262.4M | 3.6% | — | — | 20 qtrssince 2019-Q1 | Increased 62 |
XENON PHARMACEUTICALS INC | 5.7M | $261M | 3.6% | $21.21 | +117.12% | 20 qtrssince 2019-Q1 | Increased 66 |
ALNYLAM PHARMACEUTICALS INC | 1.1M | $212.7M | 2.9% | $168.03 | +13.91% | 11 qtrssince 2021-Q2 | Increased 59 |
INTRA-CELLULAR THERAPIES INC | 2.3M | $161.5M | 2.2% | — | — | 1 qtr | New 80 |
MoonLake Immunotherapeutics Class A | 2.6M | $155.8M | 2.2% | $53.80 | +12.24% | 3 qtrssince 2023-Q2 | Increased 66 |
KYMERA THERAPEUTICS INC | 3.8M | $96.1M | 1.3% | $29.78 | -14.50% | 10 qtrssince 2021-Q3 | Decreased 0 |
STRUCTURE THERAPEUTICS INC | 2.3M | $95.1M | 1.3% | $44.90 | -9.22% | 2 qtrssince 2023-Q3 | Increased 77 |
SYNDAX PHARMACEUTICALS INC | 4.2M | $91.2M | 1.3% | $21.63 | -0.07% | 13 qtrssince 2020-Q4 | Increased 70 |
Avoro Capital Advisors LLC manages $7.2B across 42 positions as of Q4 2023. Top holdings: APLS (9.2%), UTHR (8.7%), ASND (6.5%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.
Active quarter - 6 new positions, 9 exits, 20 increased. Top move: XBI (NEW, conviction 97). Portfolio: $7.2B across 42 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer